NOVO.B.DK

290.64

+4.68%↑

GMAB.DK

1,639.5

-2.96%↓

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

NOVO.B.DK

290.64

+4.68%↑

GMAB.DK

1,639.5

-2.96%↓

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

NOVO.B.DK

290.64

+4.68%↑

GMAB.DK

1,639.5

-2.96%↓

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

NOVO.B.DK

290.64

+4.68%↑

GMAB.DK

1,639.5

-2.96%↓

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

NOVO.B.DK

290.64

+4.68%↑

GMAB.DK

1,639.5

-2.96%↓

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

Home・Lista de Ações・Coloplast A-S (Class B)

Coloplast A-S (Class B)

Fechado

402.3 0.07

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

401.7

Máximo

408.5

Indicadores-chave
By Trading Economics
Rendimento	522M 1.4B
Vendas	83M 7B
P/E Médio do Setor	23.047 49.8
EPS	6.32
Rendimento de Dividendos	5.71
Margem de lucro	19.835
Funcionários	16,983
EBITDA	309M 2.3B

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+11.86% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	5.71% 2.25%
Próximos Ganhos	12 de mai. de 2026
Próxima data de dividendos	20 de mai. de 2026
Próxima data de ex-dividendo	18 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-27B 92B
Abertura anterior	402.23
Fecho anterior	402.3

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de mai. de 2026, 23:58 UTC

Ganhos

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 de mai. de 2026, 22:57 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 de mai. de 2026, 23:52 UTC

Ganhos

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 de mai. de 2026, 23:11 UTC

Ganhos

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 de mai. de 2026, 23:06 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 de mai. de 2026, 23:05 UTC

Ganhos

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 de mai. de 2026, 23:04 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 de mai. de 2026, 23:02 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 de mai. de 2026, 23:00 UTC

Conversa de Mercado

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 de mai. de 2026, 22:42 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 de mai. de 2026, 22:33 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 de mai. de 2026, 22:32 UTC

Ganhos

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie: 68% of FY Income From International >MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 de mai. de 2026, 22:29 UTC

Ganhos

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 de mai. de 2026, 22:26 UTC

Ganhos

Macquarie to End Share Buyback Extended in November>MQG.AU

7 de mai. de 2026, 22:25 UTC

Ganhos

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparação entre Pares

Variação de preço

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK 11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.